



A small molecule inhibitor of Tgf- β signaling replaces Sox2 in reprogramming by inducing Nanog

Citation

Ichida, Justin K., Joel Blanchard, Kelvin Lam, Esther Y. Son, Julia E. Chung, Dieter Egli, Kyle M. Loh, et al. 2009. A small molecule inhibitor of Tgf- β signaling replaces Sox2 in reprogramming by inducing Nanog. *Cell Stem Cell* 5, no. 5: 491–503. doi:10.1016/j.stem.2009.09.012.

Published Version

doi:10.1016/j.stem.2009.09.012

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:27409159>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)



Published in final edited form as:

Cell Stem Cell. 2009 November 6; 5(5): 491–503. doi:10.1016/j.stem.2009.09.012.

A Small Molecule Inhibitor of Tgf- β Signaling Replaces Sox2 in Reprogramming by Inducing *Nanog*

Justin K. Ichida^{1,3,*}, Joel Blanchard^{1,*}, Kelvin Lam^{1,*}, Esther Y. Son^{1,2,3,*}, Julia E. Chung^{1,2,3}, Dieter Egli^{1,3}, Kyle M. Loh¹, Ava C. Carter^{1,3}, Francesco P. Di Giorgio^{1,3}, Kathryn Koszka^{1,3}, Danwei Huangfu¹, Hidenori Akutsu⁴, David R. Liu⁵, Lee L. Rubin^{1,†}, and Kevin Eggan^{1,3,†}

¹Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138 USA

²Harvard University, Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138 USA

³Stowers Medical Institute

⁴Department of Reproductive Biology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya, Tokyo 157-8535

⁵Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138 USA

Summary

The combined activity of three transcription factors can reprogram adult cells into induced pluripotent stem (iPS) cells. However, the transgenic methods used to deliver reprogramming factors have raised concerns regarding the future utility of the resulting stem cells. These uncertainties could be overcome if each transgenic factor were replaced with a small molecule that either directly activated its expression from the somatic genome or in some way compensated for its activity. To this end, we have used high-content chemical screening to identify small molecules that can replace *Sox2* in reprogramming. We show that one of these molecules functions in reprogramming by inhibiting Tgf- β signaling in a stable and trapped intermediate cell type that forms during the process. We find that this inhibition promotes the completion of reprogramming through induction of the transcription factor *Nanog*.

Introduction

Retroviral transduction with three genes: *Sox2*, *Oct4*, and *Klf4*, can directly reprogram somatic cells to a pluripotent stem cell state (Okita et al., 2007; Takahashi et al., 2007b). Unfortunately, the resulting induced pluripotent stem (iPS) cells are suboptimal for applications in transplantation medicine and disease modeling because both the viral vectors used for gene transfer and the reprogramming factors they encode are oncogenic (Hacein-Bey-Abina et al., 2003; Nakagawa et al., 2008; Thrasher, 2007).

© 2009 II Press. All rights reserved.

[†]To whom correspondence should be addressed. eggan@mcb.harvard.edu, lee_rubin@harvard.edu.

*These authors contributed equally to this work.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

One potential solution is to identify small molecules that can efficiently reprogram cells, producing unmodified iPS cell lines better suited for downstream applications. Identification of such compounds would allow reprogramming that would not be impeded by the laborious nature of protein transduction or the safety concerns surrounding transgenic approaches (Kaji et al., 2009; Kim, 2009; Okita et al., 2008).

Several small molecules that catalyze reprogramming have already been described. Compounds that alter chromatin structure, including the DNA methyltransferase inhibitor 5-aza-cytidine (AZA) and the histone deacetylase (HDAC) inhibitor valproic acid (VPA), can increase reprogramming efficiency and even reduce the number of factors required for reprogramming (Huangfu et al., 2008a; Huangfu et al., 2008b; Mikkelsen et al., 2008; Shi et al., 2008b). Treatment with these inhibitors presumably lowers the barrier to activation of endogenous pluripotency-associated genes. However, *Oct4* and *Sox2* not only activate genes required for pluripotency, they also function to repress genes promoting differentiation. It is therefore unlikely that this class of small molecules would be sufficient to completely replace the transgenic factors. As a result, there remains a need to identify novel small molecules that can function in reprogramming.

Here, we report the discovery of compounds that can replace the central reprogramming factor *Sox2*. We demonstrate that one of these chemicals specifically acts by inhibiting Tgf- β signaling. Interestingly, this compound does not act by inducing *Sox2* expression in the target fibroblasts. Instead, we show that it enables reprogramming through the induction of *Nanog* transcription in a stable, partially reprogrammed cell type that accumulates in the absence of *Sox2*.

A Screen for Chemical Mediators of Reprogramming

To identify small molecules that function in reprogramming, we transduced fibroblasts with viral vectors encoding *Oct4*, *Klf4*, and *cMyc* and then screened for compounds that allowed for reprogramming in the absence of *Sox2*. We favored this approach because it was unbiased with respect to the mechanism by which a given chemical could function and would not only deliver chemical compounds with translational utility but also provide novel insights into the mechanisms controlling reprogramming.

Activation of an *Oct4*: GFP reporter gene in colonies with an ES cell morphology has been shown to be a stringent assay for reprogramming (Meissner et al., 2007). In mouse embryonic stem (mES) cell culture medium supplemented with VPA, retroviral transduction of 7500 *Oct4*:GFP transgenic mouse embryonic fibroblasts (MEFs) with *Oct4*, *Klf4*, *cMyc*, and *Sox2* (Boiani et al., 2004) routinely generated 100-200 GFP⁺ colonies (Figure 1A). In contrast, we observed no GFP⁺ colonies when *Sox2* was omitted (Figure 1A). We used this robust difference to identify small molecules that can replace *Sox2*.

To facilitate the identification of cellular targets and signaling pathways affected by any compounds we discovered, we utilized a library of molecules with known pharmacological targets. We transduced *Oct4*:GFP MEFs with *Oct4*, *Klf4*, and *cMyc*, and then plated 2000 cells per well in 96-well format. To each well we added one of 200 distinct compounds for 7-11 days, while also treating with 2 mM VPA for the first 7 days (Figure 1B). It was our hope that this approach would allow us to identify both compounds that required chromatin remodeling to induce reprogramming (Huangfu et al., 2008a) and compounds that did not. After 16 days, we scored each well for the presence of GFP⁺ colonies with a mES-like morphology (Figure 1C) and identified 3 independent hit compounds (Figure 1D). Two of these compounds were distinct Transforming Growth Factor- β Receptor 1 (Tgfbr1) kinase inhibitors (E-616452 and E-616451 (Figure 1E) (Gellibert et al., 2004)), while the third was a Src-family kinase inhibitor (EI-275 (Figure 1E) (Hanke et al., 1996)).

Efficient Small Molecule Replacement of Sox2

Next, we optimized the effective concentration for each hit molecule (Figure S1) and quantified the efficiency at which it synergized with VPA to replace *Sox2*. When 1500 MEFs were transduced with only *Oct4*, *Klf4*, and *cMyc* and then treated with VPA, we did not observe GFP⁺ colonies (Figure 1F). However, the addition of E-616452 (25 μ M), E-616451 (3 μ M), or EI-275 (3 μ M), led to the formation of GFP⁺ colonies with an ES cell morphology at a rate that was comparable to transduction with *Sox2* (Figure 1F).

Since the three compounds were identified in the presence of VPA, we next determined whether these molecules were dependent on this HDAC inhibitor for their reprogramming activities. We found that E-616451 and EI-275 could not induce the appearance of GFP⁺ colonies in the absence of VPA (Figure 1F), while E-616452 could do so and at a rate that was similar to a positive control transduced with the *Sox2* retrovirus (Figure 1F).

Although *cMyc* does increase the efficiency of reprogramming, it is not required for the generation of iPS cells (Nakagawa et al., 2008). Since the elimination of *cMyc* is an important step towards reducing the risk of tumor formation, we tested whether E-616452 could function in the absence of this oncogene. When added to MEFs transduced with only *Oct4* and *Klf4*, E-616452 induced the formation of GFP⁺ colonies with an efficiency similar to viral *Sox2* (Figure 1G).

Previous reports on small molecules that affect reprogramming have focused on MEFs or neural stem cells (NSCs). These cells may be reprogrammed more easily due to either their proliferative capacity or their expression of iPS factors (Huangfu et al., 2008a; Shi et al., 2008a; Shi et al., 2008b). However, it may be that chemical modulation of gene expression is cell-type specific and we therefore determined if the reprogramming compound we identified functioned in a more patient-relevant cell type. When we infected adult tail tip fibroblasts with *Oct4*, *Klf4*, and *cMyc* alone, we did not observe *Oct4*:GFP⁺ colonies. However, when we added E-616452, we readily observed reprogramming (Figure S2A). The resulting *Oct4*:GFP⁺ colonies could be expanded into cell lines that maintained homogeneous *Oct4*:GFP expression and self-renewed similarly to mES and 4-factor control iPS lines (Figure S2B). Because it could efficiently replace transgenic *Sox2* in the absence of VPA and *cMyc*, as well as in both embryonic and adult fibroblasts, we chose to further characterize E-616452 and named it RepSox, for Replacement of *Sox2*.

RepSox-reprogrammed Cells are iPS cells

Investigation of self-renewal capacity (Figure 2A), gene expression program, and pluripotency demonstrated that *Oct4*:GFP⁺ cells induced by the RepSox replacement of *Sox2* were *bona fide* iPS cells. PCR with primers specific to the *Oct4*, *Klf4*, *cMyc*, and *Sox2* transgenes confirmed that this cell line did not harbor transgenic *Sox2* (Figure S3A). Chromosomal analysis indicated it was karyotypically normal (Figure S3B).

The *Oct4*:GFP⁺ cells co-expressed alkaline phosphatase (Figure S3C) and the endogenous alleles of the *Nanog* and *Sox2* genes, suggesting pluripotency had been established (Figure 2B). The global transcriptional profile of cells reprogrammed with RepSox was similar to that of an iPS cell line produced with all four transgenes and as similar to those of mES cells (Pearson correlation coefficient = 0.95-0.97) as two distinct mES cell lines profiles were to each other (Pearson correlation coefficient = 0.96) (Figures 2C, S3D, Table S1). The profile differed significantly from that of the somatic MEFs (Figure 2C).

Cells produced with RepSox could readily form both embryoid bodies and teratomas that contained differentiated cell types of the three distinct embryonic germ layers (Figure 2E)

and S4A). In addition, we observed that these cells could respond to directed differentiation signals *in vitro* and robustly differentiate into Hb9+/Tuj1+ motor neurons (Figure 2D, Figure S5).

In order to more definitively confirm the pluripotency of cells reprogrammed with RepSox, we tested their ability to contribute to chimeric embryos *in vivo*. We labeled cells with a lentiviral transgene encoding the red fluorescent Tomato-protein and injected them into blastocysts. Both embryos and adult mice with significant contribution from the iPS cells were obtained (Figures 2F, G). Although adult mice with high contribution from the iPS cells were observed, we found it difficult to assess the contribution of these cells to the germ-line, as the majority of animals developed tumors at or before the time of sexual maturity. However, we did observe that the reprogrammed cells could contribute *Oct4::GFP* + cells to the genital ridges of embryonic chimeras, demonstrating contribution of these pluripotent cells to the germ-line (Figure 2H). Together, these results demonstrate that the RepSox-reprogrammed cells are indeed iPS cells.

RepSox Can Replace *Sox2* and *c-Myc* by Inhibiting Tgf- β Signaling

Previous studies with RepSox suggest that it can act as an inhibitor of the Tgfbr1 kinase (Gellibert et al., 2004). Therefore, we investigated whether the mechanism by which RepSox functions to replace *Sox2* is through the inhibition of Tgf- β signaling. If Tgfbr1 is the functional target of RepSox, then a structurally unrelated inhibitor of Tgf- β signaling or depletion of Tgf- β ligands from the culture medium might also replace *Sox2*. The small molecule SB431542 (Figure 3A) is known to inhibit Tgfbr1 kinase and is structurally distinct from RepSox (Inman et al., 2002). When we treated fibroblasts transduced with *Oct4*, *Klf4*, and *cMyc* with 25 μ M SB431542, we observed ~10 GFP+ colonies per 7500 cells plated (Figure 3B). Likewise, when we transduced fibroblasts in the presence of either an antibody that neutralized a variety of Tgf- β ligands (R&D Systems, AB-100-NA) or an antibody specific to Tgf- β II (R&D Systems, AB-12-NA), *Oct4::GFP*+ colonies were generated (Figure 3B). In contrast, we observed no GFP+ colonies in transductions without these Tgf- β inhibitors. These results are consistent with the notion that at least part of the mechanism by which RepSox replaces *Sox2* in reprogramming is through the inhibition of Tgf- β signaling.

Our goal was to identify molecules that specifically replace *Sox2* instead of generally increasing reprogramming efficiency. If RepSox acts specifically to replace *Sox2*, then we would not expect it to stimulate reprogramming in the presence of transgenic *Sox2*. When RepSox- or Tgf- β antibody-treated MEFs were transduced with *Oct4*, *Klf4*, *cMyc* and *Sox2*, we observed less than a 2-fold increase in the number of GFP+ colonies over the untreated controls (Figures 3C, D). The magnitude by which RepSox stimulated reprogramming in this context was significantly less than the 10-fold increase that we observed following treatment with VPA, a compound thought to increase reprogramming efficiency (Figure 1F).

In order to further investigate the specificity of *Sox2* replacement by RepSox, we tested the ability of this molecule to individually replace *Oct4*, *Klf4*, and *cMyc* in reprogramming. We found that RepSox could not induce GFP+ colonies in the absence of either *Oct4* or *Klf4*, even in the presence of VPA (Figure 3E). In contrast, we found that RepSox did increase the number of *Oct4::GFP*+ colonies by 20-fold in the absence of *cMyc*, thereby fully replacing it in reprogramming (Figure 3F). In addition, the structurally distinct Tgf- β inhibitor SB431542 and a Tgf- β -specific neutralizing antibody both increased reprogramming efficiency in the absence of *cMyc* (Figure 3G). From these experiments, we conclude that RepSox enables the replacement of the reprogramming activities provided by both

transgenic *Sox2* and *cMyc*. In both cases, these complementing activities seem to be mediated through the inhibition of Tgf- β signaling.

RepSox Replace *Sox2* by Acting on Intermediates Formed During the Reprogramming Process

The development of cocktails of small molecules that can effectively reprogram somatic cells may require a detailed knowledge of the mechanism and kinetics by which each compound acts. Therefore, we determined the optimal duration of time by which inhibition of Tgf- β signaling using RepSox can help induce reprogramming.

Initially, we pretreated MEFs with RepSox, applying the chemical for three days, and then removed it at the time of transduction with *Oct4*, *Klf4*, and *cMyc*. In these experiments, no *Oct4::GFP*⁺ colonies were formed (Figure 4A), suggesting that RepSox does not act on the initial somatic cells to replace *Sox2*. Consistent with this result, we did not detect a significant increase in the expression of endogenous *Sox2* or closely related *Sox* family members upon RepSox treatment (Figure S6A). In addition, RepSox treatment did not decrease the expression of the mesenchymal gene *Snai1* (Figure S6B), which is downregulated 5-40-fold by transduction of the 4 reprogramming factors (Mikkelsen et al., 2008). Thus, RepSox does not destabilize the pre-existing MEF transcriptional program.

In contrast, we found that RepSox did increase by 5-fold the expression of *L-Myc*, a close homolog of *cMyc* that can functionally replace it in reprogramming (Nakagawa et al., 2008) (Figure S6C). Together these data suggest that although RepSox likely functions at the level of the initial somatic cell population to replace *cMyc*, it does not act on the starting MEF population to replace *Sox2*.

Because RepSox did not seem to act directly on the fibroblasts to replace *Sox2*, we investigated whether or not it functioned on intermediates that arose during reprogramming. To address this question, we varied both the duration and timing of RepSox treatment in order to determine when it was most effective. First, we transduced 7500 MEFs with *Oct4*, *Klf4*, and *cMyc*, waited for 4 days, and then treated cultures with RepSox for either 3, 6, 9, or 18 additional days. Although a short 3-day treatment from days 4-7 induced a small number of *Oct4::GFP*⁺ colonies, the 9-day treatment from days 4-13 yielded the most *Oct4::GFP*⁺ colonies (Figure 4A).

Next, we varied the timing at which we initiated RepSox treatment, administering the compound beginning at day 4, 7, 10, 13, or 16 after transduction. We found that delaying the start of RepSox treatment increased its reprogramming potency, with optimal treatment beginning at 10 days post-transduction (Figure 4A). Together these results suggest that RepSox treatment is most effective between days 7-12 post-transduction.

To more precisely define the optimal treatment window, we determined the minimal duration of treatment required to induce reprogramming. We found that a treatment as short as only one day was sufficient to induce detectable reprogramming (Figure 4B). Delaying this short treatment yielded more reprogrammed colonies, with a sharp increase at day 11 (Figure 4B). These results indicate that RepSox is most effective at replacing *Sox2* during days 10-11 after transduction and that therefore cultures of *Oct4*, *Klf4*, and *cMyc*-transduced MEFs give rise to intermediates capable of responding to RepSox treatment. These intermediates appear at day 4 post-transduction and peak at days 10-11.

Interestingly, when we tracked the timing of the initial appearance of reprogrammed colonies as a function of the timing of RepSox administration, we found that regardless of

whether we began treatment at day 7 or day 10 post-transduction, *Oct4::GFP*⁺ colonies first appeared at day 14 (Figure S7). This suggests that RepSox may not always be the rate-limiting step in this reprogramming process and that other, RepSox-independent events take place during the formation of the RepSox-responsive intermediates.

RepSox-responsive Cell Lines

Our finding that a 24-hr pulse of RepSox can replace *Sox2* (Figure 4B) differs strikingly from the 5-10 day period of transgene expression normally required (Sridharan et al., 2009; Wernig et al., 2007) and suggests that RepSox could trigger a switch activating reprogramming. If RepSox acts to flip a switch in semi-stable intermediate cell types that accumulate in the absence of retroviral *Sox2* expression, we reasoned that it might also be possible to culture these responsive intermediates for prolonged periods of time. On the other hand, if RepSox acts during a critical window on very transient intermediates, this might not be possible. To distinguish between these models, we transduced *Oct4::GFP* MEFs with *Oct4*, *Klf4*, and *cMyc*, waited 10-14 days, and then clonally expanded 10 iPS-like, GFP-negative colonies (Figure 5A). These cell lines continued to proliferate for at least 4 passages and often maintained an iPS-like morphology (Figure 5A) but never further activated expression of *Oct4::GFP*. However, when we treated these cell lines with a 48-hour pulse of RepSox, 5-10% of the colonies in 2 of the 10 lines became *Oct4::GFP*⁺ (Figure 5A, B). These results demonstrate that partially reprogrammed cells can accumulate in the absence of *Sox2* and that some, but not all, of these cells can be clonally expanded and cultured for prolonged periods while maintaining responsiveness to RepSox.

As we had shown that this particular reprogramming molecule seems to replace *Sox2* through the inhibition of Tgf- β signaling, we sought to determine whether RepSox treatment affected Tgf- β signal transduction pathways in these responsive cell lines. To this end, we determined the levels of phosphorylated Smad3 by western blot in cell line OKM 10 both with and without RepSox treatment. Without RepSox treatment, we detected relatively high levels of phosphorylated Smad3, suggesting that Tgf- β signaling was active (Figure 5C). In contrast, treatment with 25 μ M RepSox almost completely eliminated Smad3 phosphorylation (Figure 5C), indicating that RepSox strongly inhibited Tgf- β signaling in these cells.

Because an increase in cell proliferation can also increase reprogramming efficiency (Hong et al., 2009) and possibly contribute to the replacement of transgenic *Sox2*, we measured the proliferation rate of partially reprogrammed OKM 10 cells both with and without RepSox. Treatment with RepSox decreased the proportion of cells in G2/M phase of the cell cycle (Figure 5D), indicating it does not increase the proliferation rate of these partially reprogrammed cells.

Cells That Respond To RepSox Treatment Are Distinct From Previously Described Intermediates

It has been shown that certain non-pluripotent, partially reprogrammed cell lines derived from MEFs transduced with *Oct4*, *Klf4*, *cMyc*, and *Sox2* can be fully reprogrammed with AZA or a combination of chemical inhibitors of Glycogen Synthase Kinase 3 β (GSK-3 β) and the Mek signaling pathway (2i conditions) (Mikkelsen et al., 2008; Silva et al., 2008). If the RepSox-responsive cell lines generated by overexpression of *Oct4*, *Klf4*, and *cMyc* were similar to these 4-factor cell lines, then they should also be reprogrammed by AZA or 2i. However, when we treated the 10 stable intermediate lines with either AZA or 2i for 48 hours, we found that none became reprogrammed (Figure 5B), indicating that the RepSox-responsive stable intermediates are distinct from partially reprogrammed cell lines described

previously (Mikkelsen et al., 2008; Silva et al., 2009). Consistent with these results, *in vitro* assays of kinase activity revealed that RepSox does not inhibit the targets of the 2i cocktail (Table S2).

It occurred to us that some non-pluripotent cells derived from MEFs transduced with *Oct4*, *Klf4*, *cMyc*, and *Sox2* could potentially be held in a non-pluripotent state due to inappropriate levels of transgene expression and therefore might also be responsive to RepSox treatment. To test this hypothesis, we transduced *Oct4::GFP* MEFs with *Oct4*, *Klf4*, *cMyc*, and *Sox2*, then picked and clonally expanded 9 GFP-negative colonies at day 14 after transduction (Figure S8). After treatment with RepSox, 5 of the 9 cell lines yielded reprogrammed colonies, with 2-33% of the colonies in each line becoming *Oct4::GFP*⁺ (Figures 5F, S8). These results indicate that like the stable intermediate cells generated with only *Oct4*, *Klf4*, and *cMyc*, certain incompletely reprogrammed cells generated by *Oct4*, *Klf4*, *cMyc*, and *Sox2* transduction can also be reprogrammed by RepSox.

Next, in order to determine if these RepSox-responsive intermediate cell lines derived after *Oct4*, *Klf4*, *cMyc*, and *Sox2* transduction were similar to or distinct from previously described partially reprogrammed cell lines (Mikkelsen et al., 2008), we applied AZA to all 9 lines. After 48 hours of AZA treatment and 12 subsequent days in culture, none of the RepSox-responsive cell lines expressed *Oct4::GFP* (Figure 5F). However, one of the lines that had been refractory to RepSox treatment did express *Oct4::GFP* after AZA treatment, indicating that it had undergone complete reprogramming (Figure 5F). Together, these results show that there are a variety of intermediates that can form following retroviral transduction and that they vary in their responsiveness to reprogramming molecules.

RepSox Replaces *Sox2* by Inducing *Nanog* Expression

The causal molecular events that drive reprogramming are difficult to detect because of the low efficiency at which somatic cells are successfully reprogrammed (Amabile and Meissner, 2009). However, when we administered RepSox to cell lines that had been partially reprogrammed by retroviral transduction, *Oct4::GFP* expression was induced in up to 33% of the resulting colonies (Figure 5F). We used this more efficient reprogramming system to identify the changes in gene expression induced by RepSox that enable it to bypass the requirement for transgenic *Sox2* expression.

We treated an *Oct4::GFP*-negative, partially reprogrammed cell line (OKMS 6) with RepSox and performed global gene expression analysis at 10, 24, and 48 hours following the initiation of treatment. To confirm that RepSox was inhibiting Tgf- β signaling in this intermediate cell line, we investigated expression changes in known Tgf- β -responsive genes after RepSox treatment. The *Inhibition of Differentiation* genes *Id1*, *Id2*, and *Id3* are repressed by Tgf- β signaling in mES cells (Ying et al., 2003). After treating the RepSox-responsive intermediate line OKM 10 with RepSox for 24 hours, we observed increased expression of *Id1*, *Id2*, and *Id3* (Figure S9A).

One way that RepSox could function to replace transgenic *Sox2* would be to induce the expression of endogenous *Sox2* or a *Sox*-family member, such as *Sox1* or *Sox3*, that can substitute for it in reprogramming (Nakagawa et al., 2008). However, we again did not observe a significant increase in the expression of *Sox1*, *Sox2*, *Sox3*, or any of the remaining *Sox*-family transcription factors within the first 48 hours of RepSox treatment (Figure S9B). Additionally, shRNA-mediated depletion of *Sox1*, the most potent *Sox*-family member other than *Sox2* itself (Nakagawa et al., 2008), did not affect the rate of reprogramming in the presence of RepSox (Figure S9C). These results show that RepSox does not replace *Sox2* by directly activating endogenous *Sox2* or other closely related genes.

Next, we more broadly investigated changes in transcription factor expression following chemical treatment. We did not observe an increase in endogenous *Oct4* or *Klf4* expression at early time points following RepSox treatment. However, we found that the expression of the homeodomain factor *Nanog* was among the most increased following RepSox treatment. Relative to untreated controls, *Nanog* transcription increased 4-fold within 24 hours and 10-fold after 48 hours of RepSox treatment (Figure 6A). In contrast, we did not observe a rapid increase in *Nanog* expression in 2 *Oct4::GFP*-negative intermediate cell lines that could not be fully reprogrammed using RepSox (Figure S10). Therefore, we hypothesized that RepSox might replace *Sox2* by inducing *Nanog* expression.

Because we had determined that inhibition of Tgf- β signaling by several different small molecules and antibodies can replace *Sox2*, we reasoned that if the increase in *Nanog* expression was critical for *Sox2* replacement, the alternative inhibitors of Tgf- β signaling should also upregulate *Nanog*. To test this hypothesis, we treated the RepSox-responsive cell lines with RepSox, SB431542, or neutralizing antibodies and analyzed *Nanog* expression after 48 hours. In all cases, *Nanog* expression was strongly induced within 48-96 hours (Figure 6B).

If RepSox functions by increasing *Nanog* expression, then a short pulse of RepSox should induce a persistent increase in *Nanog* expression. To test this, we treated the RepSox-responsive intermediate cell line OKM 10 with RepSox for 48 hours, withdrew RepSox and then analyzed *Nanog* expression 48 hours later. A control time point taken just before RepSox withdrawal showed a significant increase in *Nanog* transcription (Figure 6C). 48 hours after RepSox removal (96 hours after the initiation of treatment), *Nanog* expression continued to increase (Figure 6C).

If RepSox replaces *Sox2* by increasing *Nanog* expression, then a forced reduction of *Nanog* expression should inhibit or even prevent reprogramming by RepSox. To test this hypothesis, we transduced the RepSox-responsive cell line with a lentivirus encoding a short-hairpin RNA specific for *Nanog*. The *Nanog*-knockdown cells reprogrammed at a frequency that was 50-fold lower than cells transduced with an empty control vector (Figure 6D). This effect was not due to a general decrease in reprogramming efficiency or differentiation of reprogrammed cells due to *Nanog* depletion because MEFs transduced with *Oct4*, *Klf4*, *cMyc*, *Sox2*, and the *Nanog* shRNA construct only suffered a 50% loss in reprogramming efficiency (Figure 6D). These results demonstrate that increased *Nanog* expression in this context was only necessary for the replacement of *Sox2* by RepSox.

Previous reports have shown that chemical inhibition of Tgf- β signaling by SB431542 increases Bone Morphogenetic Protein (Bmp) signaling in embryonic stem cells (Xu et al., 2008). It has separately been shown that Bmp signaling in the presence of Stat3 induces *Nanog* expression in mES cells (Suzuki et al., 2006). The cross-talk between the Tgf- β and Bmp signaling pathways may be the result of a common requirement for Smad 4, which mediates transcriptional events in the nucleus (Attisano and Wrana, 2002). Similarly, we observed an increase in the levels of phosphorylated Smad1 protein and *Bmp-3* mRNA in incompletely reprogrammed intermediates following RepSox treatment (Figure S11). Furthermore, the stable, partially reprogrammed cells that responded to RepSox expressed the LIF receptor at levels equivalent to those found in mES cells (Figure S12A). Expression of this receptor suggests that its downstream signal transduction pathway could be active in these cells, resulting in the presence of activated Stat3, which is known to induce *Nanog* expression in conjunction with Bmp signaling.

Since RepSox does not act on the initial population of fibroblasts to replace *Sox2*, we would not expect *Nanog* to be upregulated in RepSox-treated MEFs. Indeed, within 7 days of

transduction of MEFs with *Oct4*, *Klf4*, and *cMyc*, we did not observe an increase in *Nanog* expression upon RepSox treatment (Figure S12B). This may be explained in part by the observation that the LIF receptor, and thus activated Stat3, were not highly expressed in these cells (Figure S12A). Because *Nanog* plays a key role in maintaining ES cells in an undifferentiated state (Chambers et al., 2003) and has been shown to enhance the efficiency of reprogramming (Silva et al., 2006; Silva et al., 2009; Yu et al., 2007), we decided to test whether *Nanog* could directly replace *Sox2* in reprogramming.

If RepSox replaces *Sox2* by inducing *Nanog* expression, then retroviral transduction of RepSox-responsive intermediate cells (line OKM 10, Figures 5A, B) with *Nanog* should reprogram them. When we transduced line OKM 10 with *Sox2* as a control, .2% of the colonies expressed *Oct4::GFP* after 10 days, indicating that reprogramming could be induced in this cell line by *Sox2* (Figures 6E, F). When we transduced the same stable intermediate cell line with *Nanog*, it could also be reprogrammed, with .3% of the colonies expressing *Oct4::GFP* after 10 days (Figures 6E, F). In contrast, transductions with *Oct4* or *Klf4* resulted in only .04% and 0% reprogramming efficiencies (Figure 6F). These results suggest that *Nanog* can indeed functionally replace *Sox2* and induce reprogramming in these stable intermediates formed from *Oct4*, *Klf4*, and *cMyc*-transduced MEFs.

If *Nanog* can complement for the omission of *Sox2* in defined factor reprogramming, then MEFs transduced with *Oct4*, *Klf4*, *cMyc*, and *Nanog* might be as efficiently reprogrammed as MEFs transduced with *Oct4*, *Klf4*, *cMyc*, and *Sox2*. When we transduced MEFs with *Oct4*, *Klf4*, *cMyc*, and *Sox2* then scored cultures 9 days later, an average of 7 *Oct4::GFP*+ colonies appeared for every 7500 cells plated (Figure 6G). A control transduction with only *Oct4*, *Klf4*, and *cMyc* yielded no *Oct4::GFP*+ colonies (Figure 6G). Similar to the positive control transduction, MEFs transduced with *Oct4*, *Klf4*, *cMyc*, and *Nanog* gave rise to an average of 5 *Oct4::GFP*+ colonies for every 7500 cells plated (Figures 6G, H). These colonies could be picked and expanded and remained *Oct4::GFP*+ for at least 5 passages (Figure S13A). Immunocytochemistry indicated that these cells strongly activated *Sox2* expression from the endogenous allele (Figure S13B). Importantly, QPCR analysis demonstrated that they also transcribed endogenous *Oct4*, *Klf4*, *Nanog*, and *Rex1* (Figure S13C), indicating that a pluripotent gene expression program had been established. Furthermore, transgene-specific QPCR analysis showed that these cells had silenced the retroviral *Oct4*, *Klf4*, and *cMyc* transgenes, (Figure S13D). Additionally, *Oct4*, *Klf4*, *cMyc*, and *Nanog*-reprogrammed cells could readily form embryoid bodies *in vitro* (Figure S13E). However, we found that leaky expression of transgenic *Nanog*, which is a potent inhibitor of embryonic stem cell differentiation (Chambers et al., 2003; Chambers et al., 2007), reduced the amount of differentiation *in vitro* (Figure S13D). We anticipate that efficient differentiation of cells created with *Oct4*, *Klf4*, *cMyc*, and *Nanog* will eventually require the use of an excisable transgenic *Nanog* cassette to completely remove ectopic *Nanog* expression. Although definitive proof of the pluripotency of these cells will be required to conclude that *Nanog* expression is sufficient to replace *Sox2* in defined factor reprogramming, our results suggest this may be the case. Taken together however, our results demonstrate that RepSox inhibition of Tgf- β signaling bypasses the need for *Sox2* in defined-factor reprogramming through the induction of *Nanog*.

Discussion

We have used a phenotypic chemical screen to identify compounds that can replace the reprogramming transcription factor *Sox2* and have confirmed the mechanism by which the most potent compound acts: RepSox replaces *Sox2* by inhibiting the broadly expressed Tgf- β signaling pathway (Attisano and Wrana, 2002) in cultures containing stable intermediate cells that are trapped in a partially reprogrammed state. This inhibition in turn leads to

sustained transcription of *Nanog*, through which reprogramming is achieved in the absence of *Sox2*. These results demonstrate the feasibility of replacing the central reprogramming transgenes with small molecules that modulate discrete cellular pathways or processes rather than by globally altering chromatin structure. Furthermore, they show that the mechanisms by which these molecules act in reprogramming can be distinct from those of the factor(s) that they replace.

Importantly, and unlike many other studies (Mikkelsen et al., 2008; Shi et al., 2008a; Shi et al., 2008b; Utikal et al., 2009), the approach that we report here for replacing *Sox2* did not rely on procurement of a highly specialized or rare cell type that already expresses *Sox2*. Furthermore, treatment with RepSox allowed the generation of iPS cells from both adult and embryonic fibroblasts with a frequency comparable to that of transduction with *Sox2*. Thus, reprogramming efficiency does not need to be compromised by small molecule replacement of transgenic factors.

We observed that instead of working on the initial fibroblast population to replace *Sox2*, RepSox acts on cellular intermediates formed by overexpression of *Oct4*, *Klf4*, and *cMyc*. Without RepSox treatment, these intermediates are trapped in an unproductive state. Unlike previously described partially reprogrammed cells (Mikkelsen et al., 2008; Silva et al., 2009), the RepSox-responsive intermediates could not be reprogrammed with AZA or 2i treatment, suggesting that they are distinct. In addition, we found that RepSox does not target any of the kinases inhibited by the 2i cocktail, indicating that it works through a different mechanism. Furthermore, 4-factor intermediates that reprogram with RepSox treatment are not responsive to AZA, indicating that they also are distinct.

These findings demonstrate that reprogramming can proceed in a step-wise fashion through different intermediates. Just as in a geographical setting where there are multiple routes to travel from point A to point B, there exist different intermediate states or “way stations” that somatic cells can transit through on the way to complete reprogramming. Interestingly, although our results indicate that defined-factor reprogramming with *Oct4*, *Klf4*, *cMyc*, and *Sox2* can occur in the absence of *Nanog*, its induction is required for chemical reprogramming of both our RepSox-responsive intermediates and the recently described 2i-responsive intermediates made from *Oct4*, *Klf4* and *cMyc* transduction of cells that express *Sox2* endogenously (Silva et al., 2009). This indicates that commonalities can exist in the reprogramming routes used by some sets of distinct intermediates.

Originally, we found it surprising that *Nanog* was not included in the initial set of defined reprogramming factors (Takahashi and Yamanaka, 2006) given its critical role in maintaining pluripotency in ES cells (Boyer et al., 2005; Chambers et al., 2003) and its ability to stimulate reprogramming by cell-fusion (Silva et al., 2006). However, Takahashi and Yamanaka reported that a combination of 9 factors that included *Oct4*, *Klf4*, *cMyc*, and *Nanog*, but not *Sox2*, generated iPS colonies at a detectable rate (Takahashi and Yamanaka, 2006). This combination of factors included other genes that may have inadvertently lowered the rate of reprogramming, causing the combination of *Oct4*, *Klf4*, *cMyc*, and *Nanog* to be overlooked. Consistent with these data, work by Niwa and co-workers using inducible *Sox2*-null mES cells demonstrated that *Sox2* is dispensable for modulation of the Oct-Sox enhancers that regulate pluripotent-specific gene expression and instead mainly governs pluripotency in ES cells by regulating the expression of *Oct4* through other factors (Masui et al., 2007). Therefore, it is possible that *Nanog* may alleviate the requirement for *Sox2* in reprogramming by stimulating or maintaining *Oct4* expression. Indeed, *Nanog* is capable of maintaining *Oct4* expression in mES cells (Chambers et al., 2003). Thompson and co-workers also reported that *NANOG* expression enhanced the reprogramming of human fibroblasts, but that it was not able to replace *SOX2* in the presence of only *OCT4*

and *LIN-28* (Yu et al., 2007). This may indicate that *Klf4* is required for *Nanog* to function optimally in reprogramming and suggests that either they or the genes they modulate interact during the reprogramming process.

It is well known that approximately 90% of genes with promoters bound by OCT4 and SOX2 in human ES cells are also bound by NANOG (Boyer et al., 2005). Our result suggests that either *Nanog* or *Sox2* may be sufficient to collaborate with *Oct4* to modulate these genes and drive reprogramming. Although *Nanog* is not required for pluripotency, it safeguards ES cells against neuroectodermal and, to a more limited extent, mesodermal differentiation (Chambers et al., 2007; Vallier et al., 2009). Therefore, it is possible that *Nanog* functions in reprogramming by repressing differentiation signals, assisting in the transition to an undifferentiated state.

Interestingly, we found that RepSox is also able to functionally replace *cMyc* in reprogramming. Together, these observations highlight the fact that small molecules may functionally replace reprogramming transcription factors at either early or late stages of the process and that they can act by different mechanisms – by inducing the expression of the gene itself, or a closely related family member, or an unrelated gene that can functionally rescue the omission of the reprogramming transcription factor.

Our observation that a one-day treatment with RepSox can relieve the requirement for transgenic *Sox2* indicates that unlike reprogramming using transgenic *Oct4*, *Klf4*, and *Sox2*, where each transgene must be expressed for several days (Sridharan et al., 2009; Stadtfeld et al., 2008), small molecules can act as switches to induce stable changes in gene expression that promote the completion of reprogramming. This could be an important concept for achieving purely chemical reprogramming since our data show that chemicals such as RepSox can affect cellular processes differently depending on the timing of administration.

As we have shown here, there need not always be a discrete, one-to-one mapping between the functions of the reprogramming factors and their chemical replacements. Thus it may be that reiterative screening in the presence of *Sox2* replacement molecules will be required to identify compounds that can act in concert to replace *Oct4* and *Klf4*. However, it will be of significant interest to determine whether the novel reprogramming compounds we have identified can collaborate with those previously described (Marson et al., 2008; Shi et al., 2008a; Silva et al., 2008) to replace the remaining reprogramming genes, opening a route to purely chemical reprogramming.

Experimental Procedures

Retroviral Infection

Retroviral infections were performed as previously described using the pMXs vector (Takahashi et al., 2007a). MEFs were infected with two to three pools of viral supernatant during a 72-hour period. The first day that viral supernatant was added was termed “day 1 post-infection.” For quantification, *Oct4*:GFP⁺ colonies were counted at day 30 post-infection unless otherwise stated.

Small Molecule Screens

On day 4 post-infection, infected MEFs were trypsinized and re-seeded on irradiated feeders in 96-well plates at 2000 cells/well and cultured in mouse ES cell media (Knockout DMEM, 15% Hyclone FBS, L-glutamine, penicillin/streptomycin, nonessential amino acids, β -mercaptoethanol, and 1000 U/ml LIF). The next day, compound stock solutions diluted in DMSO and VPA (Sigma) were added at a final concentration of 1 μ M and 2 mM, respectively. VPA was removed after 1 week, and compound was re-applied every other day

with each media change. Plates were scored for GFP+ colonies after 11 days of compound treatment.

Quantification of *Oct4*::GFP+ iPS Cells Generated with Small Molecule Hit Compounds, SB431542, and Tgf- β antibodies

Retroviral infection and compound or antibody treatment was performed as in the original chemical screen. To quantify the numbers of GFP+ colonies produced in different conditions, the number of colonies in each well was counted and at least 2 different wells were counted and averaged. Concentrations of compounds and antibodies were the following: VPA (Sigma)- 2 mM, RepSox (Calbiochem)- 25 μ M or 1 μ M as noted, E-616451 (Calbiochem)- 3 μ M, EI-275 (Biomol)- 3 μ M, SB431542 (Sigma)- 25 μ M or 2 μ M as noted, Tgf β II-specific antibody (R&D Systems, AB-12-NA)- 10 μ g/ml, pan-Tgf β antibody (R&D Systems, AB-100-NA)- 10 μ g/ml. Unless otherwise noted, all chemical treatments were continuous from initial administration at day 4-5 post-infection until GFP+ colonies were scored at day 30 post-transduction. Fresh chemical was added at each media change.

Chemical Reprogramming of Stable Intermediate Cell Lines

Oct4::GFP-negative colonies in *Oct4*, *Klf4*, and *cMyc* or *Oct4*, *Klf4*, *cMyc*, and *Sox2*-infected MEF cultures were picked, plated on irradiated feeders, and single colonies were picked after 1 week. The resulting cell lines were passaged with trypsin and grown in mES media on feeders until passage 4, at which time they were treated with RepSox (25 μ M), AZA (500 μ M), or both for 48 hours. For 2i treatment, CHIR99021 (Stemgent) was used at 3 μ M and PD0325901 (Stemgent) was used at 1 μ M. *Oct4*::GFP+ colonies were scored 12 days after the beginning of chemical treatment. Treatments were performed in mES media containing FBS unless otherwise noted.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank E. Kiskinis, A. Arvanites, S. Bobrowicz, Weisenthal, R. Maehr, A. Kweudjeu, R. Gali, M. Yamaki, E. Massassa, R. Martinez, K. and Rosowski for technical assistance and S. Sullivan, K. Niakan, K. Rodolfa, S. Mekhoubad, I. Tabansky, C. Sasaki, D. Melton, and S. Chen for helpful discussions. This work was made possible by support provided by the Harvard Stem Cell Institute to L.R. and K.E. and by support from the NIH grant R01 HD046732-01A1 to K.E. E.S. and D.L. acknowledge support from the NIH (GM065400) and from the Howard Hughes Medical Institute. J.K.I. and F.P.D. are New York Stem Cell Foundation postdoctoral fellows. D.H. is a Helen Hay Whitney postdoctoral fellow. K.E. is a fellow of the John D. and Catherine T. MacArthur Foundation.

The authors are filing a patent based on the results reported in this paper.

References

- Amabile G, Meissner A. Induced pluripotent stem cells: current progress and potential for regenerative medicine. *Trends Mol Med*. 2009; 15:59–68. [PubMed: 19162546]
- Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. *Science*. 2002; 296:1646–1647. [PubMed: 12040180]
- Boiani M, Kehler J, Scholer HR. Activity of the germline-specific Oct4-GFP transgene in normal and clone mouse embryos. *Methods Mol Biol*. 2004; 254:1–34. [PubMed: 15041753]
- Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell*. 2005; 122:947–956. [PubMed: 16153702]

- Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. *Cell*. 2003; 113:643–655. [PubMed: 12787505]
- Chambers I, Silva J, Colby D, Nichols J, Nijmeijer B, Robertson M, Vrana J, Jones K, Grotewold L, Smith A. Nanog safeguards pluripotency and mediates germline development. *Nature*. 2007; 450:1230–1234. [PubMed: 18097409]
- Gellibert F, Woolven J, Fouchet MH, Mathews N, Goodland H, Lovegrove V, Laroze A, Nguyen VL, Sautet S, Wang R, et al. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. *J Med Chem*. 2004; 47:4494–4506. [PubMed: 15317461]
- Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science*. 2003; 302:415–419. [PubMed: 14564000]
- Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. *J Biol Chem*. 1996; 271:695–701. [PubMed: 8557675]
- Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. *Nature*. 2009; 460:1132–1135. [PubMed: 19668191]
- Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. *Nat Biotechnol*. 2008a; 26:795–797. [PubMed: 18568017]
- Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, Muhlestein W, Melton DA. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. *Nat Biotechnol*. 2008b
- Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. *Mol Pharmacol*. 2002; 62:65–74. [PubMed: 12065756]
- Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. *Nature*. 2009
- Kim D, Kim C, Moon J, Chung Y, Chang M, Han B, Ko S, Yang E, Cha KY, Lanza R, Kim K. Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins. *Cell Stem Cell*. 2009; 4
- Marson A, Foreman R, Chevalier B, Bilodeau S, Kahn M, Young RA, Jaenisch R. Wnt signaling promotes reprogramming of somatic cells to pluripotency. *Cell Stem Cell*. 2008; 3:132–135. [PubMed: 18682236]
- Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, Takahashi K, Okochi H, Okuda A, Matoba R, Sharov AA, et al. Pluripotency governed by *Sox2* via regulation of *Oct3/4* expression in mouse embryonic stem cells. *Nature Cell Biology*. 2007; 9:11.
- Meissner A, Wernig M, Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. *Nat Biotechnol*. 2007; 25:1177–1181. [PubMed: 17724450]
- Mikkelsen TS, Hanna J, Zhang X, Ku M, Wernig M, Schorderet P, Bernstein BE, Jaenisch R, Lander ES, Meissner A. Dissecting direct reprogramming through integrative genomic analysis. *Nature*. 2008; 454:49–55. [PubMed: 18509334]
- Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. *Nat Biotechnol*. 2008; 26:101–106. [PubMed: 18059259]
- Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. *Nature*. 2007; 448:313–317. [PubMed: 17554338]
- Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors. *Science*. 2008

- Shi Y, Despons C, Do JT, Hahm HS, Scholer HR, Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. *Cell Stem Cell*. 2008a; 3:568–574. [PubMed: 18983970]
- Shi Y, Do JT, Despons C, Hahm HS, Scholer HR, Ding S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. *Cell Stem Cell*. 2008b; 2:525–528. [PubMed: 18522845]
- Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen TW, Smith A. Promotion of reprogramming to ground state pluripotency by signal inhibition. *PLoS Biol*. 2008; 6:e253. [PubMed: 18942890]
- Silva J, Chambers I, Pollard S, Smith A. Nanog promotes transfer of pluripotency after cell fusion. *Nature*. 2006; 441:997–1001. [PubMed: 16791199]
- Silva J, Nichols J, Theunissen TW, Guo G, van Oosten AL, Barrandon O, Wray J, Yamanaka S, Chambers I, Smith A. Nanog is the gateway to the pluripotent ground state. *Cell*. 2009; 138:722–737. [PubMed: 19703398]
- Sridharan R, Tchieu J, Mason MJ, Yachechko R, Kuoy E, Horvath S, Zhou Q, Plath K. Role of the murine reprogramming factors in the induction of pluripotency. *Cell*. 2009; 136:364–377. [PubMed: 19167336]
- Stadtfeld M, Maherali N, Breault DT, Hochedlinger K. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. *Cell Stem Cell*. 2008; 2:230–240. [PubMed: 18371448]
- Suzuki A, Raya A, Kawakami Y, Morita M, Matsui T, Nakashima K, Gage FH, Rodriguez-Esteban C, Izpisua Belmonte JC. Nanog binds to Smad1 and blocks bone morphogenetic protein-induced differentiation of embryonic stem cells. *Proc Natl Acad Sci U S A*. 2006; 103:10294–10299. [PubMed: 16801560]
- Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. *Nat Protoc*. 2007a; 2:3081–3089. [PubMed: 18079707]
- Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*. 2007b; 131:861–872. [PubMed: 18035408]
- Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006; 126:663–676. [PubMed: 16904174]
- Thrasher, AJa; G, HB. Severe adverse event in clinical trial of gene therapy for X-SCID. 2007. <http://www.wasg.org/UserFiles/XSCIDstatement.pdf>
- Utikal J, Maherali N, Kulalert W, Hochedlinger K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. *J Cell Sci*. 2009; 122:3502–3510. [PubMed: 19723802]
- Vallier L, Mendjan S, Brown S, Chng Z, Teo A, Smithers LE, Trotter MW, Cho CH, Martinez A, Rugg-Gunn P, et al. Activin/Nodal signalling maintains pluripotency by controlling Nanog expression. *Development*. 2009; 136:1339–1349. [PubMed: 19279133]
- Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. *Nature*. 2007; 448:318–324. [PubMed: 17554336]
- Xu RH, Sampsel-Barron TL, Gu F, Root S, Peck RM, Pan G, Yu J, Antosiewicz-Bourget J, Tian S, Stewart R, et al. NANOG is a direct target of TGFbeta/activin-mediated SMAD signaling in human ESCs. *Cell Stem Cell*. 2008; 3:196–206. [PubMed: 18682241]
- Ying QL, Nichols J, Chambers I, Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. *Cell*. 2003; 115:281–292. [PubMed: 14636556]
- Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, et al. Induced pluripotent stem cell lines derived from human somatic cells. *Science*. 2007; 318:1917–1920. [PubMed: 18029452]




Figure 1. Identification of Small Molecules That Replace of Sox2

(A) *Oct4::GFP*+ colonies form readily in *Oct4*, *Klf4*, *cMyc*, and *Sox2*-infected MEF cultures and do not form in *Oct4*, *Klf4*, and *cMyc*-infected MEF cultures. Scale bars = 500 μ m.

(B) Overview of chemical screen for replacement of *Sox2*.

(C) A P0 colony from *Oct4*, *Klf4*, and *cMyc*-infected MEFs + RepSox that displays a mES-like morphology and is *Oct4::GFP*+. Scale bars = 200 μ m.

(D) Number of *Oct4::GFP*+ colonies detected for each hit in the primary screen after transduction of *Oct4*, *Klf4*, and *cMyc* and VPA treatment.

(E) Chemical structures of E-616452, E-616451, and EI-275, with the optimal concentrations for reprogramming listed.

(F) Quantification of small molecule replacement of *Sox2* in *Oct4*, *Klf4*, and *cMyc*-infected MEFs with and without VPA treatment.

(G) *Sox2* replacement by RepSox is not dependent on *cMyc* (no VPA treatment).




Figure 2. RepSox-reprogrammed Cells Are Pluripotent

(A) An *Oct4::GFP*+ iPS line that was derived from a culture of RepSox-treated *Oct4*, *Klf4*, and *cMyc*-infected MEFs (OKM + RepSox line 1) displays the characteristic mES-like morphology and self-renewal properties. Passage 11. Scale bars = 500 μ m.

(B) Antibody staining of OKM + RepSox line 1 cells shows that they express markers of pluripotent stem cells Sox2 and Nanog. Scale bars = 100 μ m.

(C) Microarray scatter plots showing that the global gene expression profile of OKM + RepSox line 1 is highly similar to that of mES line V6.5 and very different from that of somatic MEFs.

(D) Motor neurons differentiated *in vitro* from OKM + RepSox line 1. Scale bar = 200 μ m.

(E) Teratomas containing cells of all three germ layers formed by injection of OKM + RepSox line 1 cells into nude mice.

(F) E12.5 chimeric mouse embryo (left, vs. non-chimeric littermate on the right) showing a high amount of contribution from OKM + RepSox line 1 cells constitutively expressing the dTomato red fluorescent protein.

(G) 8 week-old chimeric mouse formed by injection of OK + RepSox line 1 cells (C57BL6 genetic background) into an ICR blastocyst.

(H) *Oct4::GFP*⁺ cells derived from an OKM + RepSox cell line are present in the genital ridge of a male embryo at 13.5 d.p.c.




Figure 3. RepSox Specifically Replaces Sox2 by Inhibiting Tgf- β Signaling

(A) Chemical structure of SB431542, an inhibitor of Tgfr1 activity.

(B) Inhibition of Tgf- β signaling by treatment of *Oct4*, *cMyc*, and *Sox2*-infected MEFs with SB431542 or TGF- β neutralizing antibodies replaces *Sox2*.

(C) RepSox does not increase the efficiency of *Oct4*::GFP+ colony induction in *Oct4*, *Klf4*, *cMyc*, and *Sox2*-infected MEFs.

(D) Inhibition of Tgf- β signaling by TGF- β neutralizing antibodies does not increase the efficiency of *Oct4*::GFP+ colony induction in *Oct4*, *Klf4*, *cMyc*, and *Sox2*-infected MEFs.

(E) RepSox does not replace transgenic *Oct4* or transgenic *Klf4* in reprogramming. We observed no *Oct4*::GFP+ colonies in RepSox-treated *Klf4*, *cMyc*, *Sox2*-infected MEFs or *Oct4*, *cMyc*, *Sox2*-infected MEFs out of 30,000 cells plated both with and without VPA treatment. We routinely observe 30-40 *Oct4*::GFP+ colonies when we plate the same number of *Oct4*, *Klf4*, *cMyc*-infected MEFs and treat with RepSox.

(F) RepSox can replace *cMyc* in reprogramming. Cells were transduced with *Oct4*, *Klf4*, and *cMyc* and treated with RepSox continuously starting at day 5 post-infection.

(G) Inhibition of Tgf- β signaling can replace *cMyc* in reprogramming. Cells were transduced with *Oct4*, *Klf4*, and *cMyc* and treated with inhibitors of Tgf- β signaling continuously starting at day 5 post-infection.




Figure 4. A Short Pulse of RepSox is Sufficient for *Sox2* Replacement and Most Effective at Later Time Points Post-infection

(A) Graph showing the number of *Oct4*::GFP+ colonies induced by various timings of RepSox treatment of *Oct4*, *cMyc*, and *Sox2*-infected MEFs in mES medium. Colonies were counted at 24 days post-infection.

(B) Timecourse of RepSox treatment showing the number of *Oct4*::GFP+ colonies induced by a 24-hr pulse of RepSox on *Oct4*, *cMyc*, and *Sox2*-infected MEFs in serum-free mES medium with knockout serum replacement (KSR mES). Colonies were counted at 24 days post-infection. Shown are average colony numbers +/- the standard deviation.




Figure 5. Stable Intermediates Can Be Reprogrammed by RepSox

(A) Stable *Oct4*::GFP-negative cell lines derived from *Oct4*::GFP-negative colonies in *Oct4*, *Klf4*, and *cMyc*-infected MEF cultures can be reprogrammed by RepSox. Scale bars in “OKM line 10 + RepSox” panels = 500 μ m, all other scale bars = 200 μ m.

(B) 2 of 10 stable, non-pluripotent intermediate cell lines derived from MEFs transduced with *Oct4*, *Klf4*, and *cMyc* can be reprogrammed with RepSox treatment but none can be reprogrammed with AZA treatment.

(C) Western blot for phospho-Smad3 showing that RepSox inhibits Tgf- β signaling in line OKM 10 (OKM 10) cells.

(D) RepSox does not increase the proliferation of OKM 10 cells.

(E) Line OKM 10 can be reprogrammed with RepSox treatment but not with AZA or 2i, indicating it is distinct from cell lines that can be reprogrammed by AZA or 2i.

(F) Stable *Oct4*::GFP-negative cell lines derived from *Oct4*::GFP-negative colonies in *Oct4*, *Klf4*, *cMyc* and *Sox2*-infected MEF cultures can be reprogrammed by RepSox or by AZA, but lines responsive to RepSox are not responsive to AZA alone and lines responsive to AZA are not responsive to RepSox alone, indicating the presence of two different types of stable intermediates in the reprogramming cultures.




Figure 6. RepSox Replaces Sox2 by Inducing *Nanog* Expression

(A) RepSox treatment of RepSox-responsive line OKMS 6 strongly increases *Nanog* mRNA levels. Data were generated by microarray analysis and are relative to untreated controls. *Nanog* is induced faster and more significantly than *Sox2*, indicating it is upregulated before fully reprogrammed cells form.

(B) RT-PCR analysis showing that inhibition of Tgf- β signaling increases *Nanog* expression in the RepSox-responsive intermediate line OKMS 7.

(C) A pulse of RepSox induces a persistent increase in *Nanog* expression in the RepSox-responsive intermediate line OKM 10. OKM 10 cells were treated with 25 μ M RepSox for 48 hours and RNA samples were taken at 0, 48, and 96 hours (48 hours after removal of RepSox) and analyzed by RT-PCR.

(D) shRNA-mediated knockdown of *Nanog* in OKM 10 cells inhibits replacement of *Sox2* by RepSox.

(E) Pictures of reprogrammed *Oct4::GFP*⁺ colonies induced by *Sox2* (A) or *Nanog* (B) transduction of line OKM 10. Scale bars = 200 μ m.

(F) *Nanog* transduction can reprogram line OKM 10 at a similar efficiency as *Sox2* transduction.

(G) *Nanog* can substitute for *Sox2* in defined-factor reprogramming of somatic fibroblasts.

(H) Picture of a reprogrammed *Oct4::GFP*⁺ colony induced by *Oct4*, *Klf4*, *cMyc* and *Nanog*-transduction of MEFs. Scale bars = 100 μ m.